Form 4: Solenis Therapeutics Inc. Executive Michael F. Huang Reports Stock Sales to Cover Tax Obligations

Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics Inc., sold shares of common stock on March 27, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 27, 2025, Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics Inc., reported the sale of common stock.
• The sales were executed in multiple transactions at varying prices, ranging from approximately $65.15 to $72.80 per share.
• A total of 10,000 shares were also acquired through the exercise of employee stock options at a price of $21.93 per share.
• The sales were made to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following these transactions, Huang directly owns 36,817 shares of common stock and holds options for 110,000 shares.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock sales to cover tax obligations, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The stock sales by a company executive could have a minor negative impact on shareholder sentiment, although the stated reason mitigates this concern.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Sale, Stock Options, Restricted Stock Units, SLNO, Solenis Therapeutics, Insider Trading